/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

S

Sharon Wilks

Texas Oncology(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

88

Papers

4.4K

Citations

22

h-index

33

i10-index

Sharon Wilks is an academic researcher from Texas Oncology. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology & Advanced Breast Cancer Therapies. The author has an h-index of 22, co-authored 75 publications.

ORCID: 0000-0003-2004-4273

Research Topics

HER2/EGFR in Cancer Research Cancer Treatment and Pharmacology Advanced Breast Cancer Therapies Breast Cancer Treatment Studies Monoclonal and Polyclonal Antibodies Research

Papers by this author

works

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3

2016 · Journal of Clinical Oncology · 165 citations

https://doi.org/10.1200/jco.2015.63.9161

Fabrice André Sara A. Hurvitz Angelica Fasolo Ling‐Ming Tseng

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer

2021 · Journal of Clinical Oncology · 107 citations

https://doi.org/10.1200/jco.20.02272

Aditya Bardia Virginia Kaklamani Sharon Wilks Amy Weise

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

2014 · Clinical Breast Cancer · 69 citations

https://doi.org/10.1016/j.clbc.2014.04.004

Sharon Wilks Shannon Puhalla Joyce O’Shaughnessy Lee S. Schwartzberg

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

2021 · European Journal of Cancer · 67 citations

https://doi.org/10.1016/j.ejca.2021.03.047

Joyce O’Shaughnessy Susana Sousa Josefina Cruz Lesley Fallowfield

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

2021 · European Journal of Cancer · 67 citations

https://doi.org/10.1016/j.ejca.2021.03.047

Joyce O’Shaughnessy Susana Sousa Josefina Cruz Lesley Fallowfield

Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer

2021 · JAMA Network Open · 33 citations

https://doi.org/10.1001/jamanetworkopen.2021.4103

Joyce O’Shaughnessy Kristi McIntyre Sharon Wilks Ling Ma

Research topics

topics

HER2/EGFR in Cancer Research

Cancer Treatment and Pharmacology

Advanced Breast Cancer Therapies

Breast Cancer Treatment Studies

Monoclonal and Polyclonal Antibodies Research

Chat about Author

Papers

Chat

Click to start Chat